Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 11/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84415 | 0.89 | CDK4 (0.52) | CDK4CDK2GSK3BRAPGEF4BRAF | |
| SCHEMBL10224747 | 0.83 | SCN5A (0.41) | CDK4CDK2GSK3BSTK17BSTK17A | |
| SCHEMBL13524613 | 0.80 | GSK3B (0.55) | CDK4CDK2GSK3BRAPGEF4BRAF | |
| SCHEMBL13524817 | 0.79 | AURKA (0.63) | LMNA | |
| SCHEMBL2956376 | 0.71 | PLK1 (0.68) | CDK4CDK2GSK3BBRAFMAPK14 | |
| SCHEMBL6809405 | 0.71 | CDK4 (0.64) | CDK4CDK2CCND3CCNA2CCNA1 | |
| SCHEMBL4383661 | 0.71 | CDK2 (0.53) | CDK4CDK2GSK3BBRAFMAPK14 | |
| SCHEMBL6158114 | 0.71 | CDK2 (0.62) | CDK4CDK2CCNA2CCNA1 | |
| SCHEMBL15181324 | 0.71 | SCN9A (0.44) | CDK4CDK2GSK3BSTK17BSTK17A | |
| SCHEMBL2087309 | 0.71 | GSK3B (0.61) | CDK4CDK2GSK3BBRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDK4 12/4885CDK2 20/4885GSK3B 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.